0QGJ Stock Overview
A biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Medigene AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.95 |
| 52 Week High | €5.84 |
| 52 Week Low | €1.95 |
| Beta | 0.86 |
| 11 Month Change | -14.10% |
| 3 Month Change | -19.42% |
| 1 Year Change | -46.72% |
| 33 Year Change | -74.81% |
| 5 Year Change | -85.11% |
| Change since IPO | -95.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QGJ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -12.6% | 1.5% | 2.2% |
| 1Y | -46.7% | -17.9% | 8.8% |
Return vs Industry: 0QGJ underperformed the UK Biotechs industry which returned -21.9% over the past year.
Return vs Market: 0QGJ underperformed the UK Market which returned 10.3% over the past year.
Price Volatility
| 0QGJ volatility | |
|---|---|
| 0QGJ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QGJ's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0QGJ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 87 | Selwyn Ho | www.medigene.com |
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Medigene AG Fundamentals Summary
| 0QGJ fundamental statistics | |
|---|---|
| Market cap | €29.90m |
| Earnings (TTM) | -€15.93m |
| Revenue (TTM) | €7.45m |
4.0x
P/S Ratio-1.9x
P/E RatioIs 0QGJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QGJ income statement (TTM) | |
|---|---|
| Revenue | €7.45m |
| Cost of Revenue | €1.49m |
| Gross Profit | €5.95m |
| Other Expenses | €21.89m |
| Earnings | -€15.93m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 79.94% |
| Net Profit Margin | -213.98% |
| Debt/Equity Ratio | 0% |
How did 0QGJ perform over the long term?
See historical performance and comparison